A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer.

A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer. BMC Cancer. 2017 Sep 12; 17(1):646.

View in: PubMed

subject areas

Adult
Aged
Antineoplastic Agents, Immunological
Bayes Theorem
Breast Neoplasms
Carcinoma, Squamous Cell
Dose-Response Relationship, Drug
Esophageal Neoplasms
Female
Head and Neck Neoplasms
Humans
Male
Maximum Tolerated Dose
Middle Aged
Receptor, ErbB-2
Receptor, ErbB-3
Stomach Neoplasms

authors with profiles

Ravi Salgia
Ezra Cohen